CAPRIN-1 Targeting Antibody for Selective Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using antibodies targeting cancer antigens often result in significant side effects due to the expression of these antigens in both cancer and normal cells, leading to damage of both cell types.
Innovation Solution
Development of an antibody specifically targeting CAPRIN-1, an intracellular protein that is specifically expressed on the surface of cancer cells, which is designed to have improved antitumor activity and minimized side effects by using a humanized, chimeric, single-chain, or bispecific antibody with specific heavy and light chain variable regions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies targeting cancer antigens are used for cancer treatment, then antitumor activity is improved, but side effects worsen due to antigen expression in both cancer and normal cells
Solution Approach 1:
The patent applies local quality by developing an antibody that specifically recognizes CAPRIN-1 protein localized on the surface of cancer cells, rather than targeting antigens present in both cancer and normal cells. This selective targeting ensures that the therapeutic effect is concentrated on cancer cells while sparing normal cells, thereby improving the therapeutic index by resolving the contradiction between antitumor activity and side effects
Solution Approach 2:
The patent segments the target population by identifying CAPRIN-1 as a cancer-specific marker that distinguishes cancer cells from normal cells. By segmenting the antibody's target specificity to only cancer cells expressing CAPRIN-1, the treatment achieves high antitumor activity while avoiding damage to normal cells that do not express this marker, thus resolving the side effect issue
2Ease of manufacture
If conventional antibodies targeting broadly expressed antigens are used, then ease of manufacture is improved, but manufacturing precision worsens due to lack of cancer-specificity
Solution Approach 1:
The patent applies parameter changes by modifying the antibody's specificity parameter to target CAPRIN-1, a protein with altered expression patterns in cancer cells compared to normal cells. This parameter change in antigen specificity allows the antibody to maintain manufacturability while achieving precise cancer-specific targeting, resolving the contradiction between ease of manufacture and manufacturing precision
Data Source
AI summary
An object of the present invention is to prepare an antibody that targets CAPRIN-1 specifically expressed on the surface of cancer cells and is superior in antitumor activity to conventional antibodies and to provide use of the antibody as a therapeutic and/or preventive agent for cancer. The present invention provides use of an antibody targeting an identified cancer antigenic protein specifically expressed on the surface of cancer cells as a therapeutic and/or preventive agent for cancer, specifically, a pharmaceutical composition for treatment and/or prevention of cancer, comprising as an active ingredient an antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein, the antibody or the fragment thereof comprising a heavy chain variable region comprising amino acid sequences represented by SEQ ID NOs: 5, 6, and 7 and a light chain variable region comprising amino acid sequences represented by SEQ ID NOs: 9, 10, and 11.